Royce & Associates LP Decreases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Royce & Associates LP lessened its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 297,198 shares of the company’s stock after selling 4,000 shares during the period. Royce & Associates LP owned about 0.89% of TransMedics Group worth $46,660,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets raised its position in TransMedics Group by 35.1% in the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company’s stock valued at $1,286,000 after purchasing an additional 4,518 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of TransMedics Group by 337,462.5% during the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after buying an additional 26,997 shares during the period. ProShare Advisors LLC lifted its position in TransMedics Group by 7.8% during the 1st quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock worth $434,000 after acquiring an additional 427 shares in the last quarter. Entropy Technologies LP purchased a new position in TransMedics Group in the 1st quarter worth approximately $201,000. Finally, State Board of Administration of Florida Retirement System grew its position in TransMedics Group by 8.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after acquiring an additional 780 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TMDX shares. Robert W. Baird reduced their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Oppenheimer lowered their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a research note on Tuesday, October 29th. Finally, Stephens raised their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Trading Down 4.7 %

NASDAQ:TMDX opened at $88.36 on Friday. The company has a market cap of $2.97 billion, a PE ratio of 94.00 and a beta of 2.08. The business’s 50 day moving average is $127.92 and its two-hundred day moving average is $139.56. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52 week low of $63.85 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter last year, the business earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. On average, analysts predict that TransMedics Group, Inc. will post 1.07 EPS for the current year.

Insider Activity

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. The trade was a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 36,958 shares of company stock valued at $5,230,528. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.